WuXi XDC is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) specialising in antibody-drug conjugates (ADCs) and other bioconjugates.

Headquartered in Wuxi, China, with additional operations in Shanghai and Changzhou, WuXi XDC offers comprehensive, end-to-end services for the discovery, development, and cGMP manufacturing of bioconjugates. Their state-of-the-art laboratories and manufacturing facilities are strategically located within a 200-kilometre radius, facilitating efficient logistics and project management. This proximity enables significant reductions in development timelines and costs, benefiting a diverse clientele of over 400 global partners.

Key Products and Services

• Bioconjugation Discovery: Expert teams provide R&D capabilities to generate, engineer, evaluate, and optimise ADCs and other bioconjugates, identifying ideal lead candidates to enhance drug discovery efficiency.

• Process Development: Comprehensive services include process development, scale-up, and tech transfer to GMP manufacturing for ADCs and other bioconjugates, ensuring seamless progression from development to production.

• Analytical Development: Advanced analytical services support the characterisation and quality control of bioconjugates, ensuring compliance with regulatory standards.

• Formulation and Drug Product Development: Design and development of liquid, frozen, or lyophilised dosage forms for a wide range of bioconjugates, including specialised formulations for products containing nanoparticles and other complex molecules.

• GMP Manufacturing: End-to-end manufacturing services encompass antibody intermediates, bioconjugate drug substances, and drug products, supported by cutting-edge facilities equipped with automated systems. Recent expansions have doubled capacity, underscoring commitment to meeting the growing demands of the global bioconjugate industry.

• Payload and Linker R&D and Manufacturing: Integrated discovery, CMC development, and cGMP manufacturing of chemical payloads and linkers used in ADCs and other bioconjugates, featuring a library of ready-made compounds and advanced technologies such as catalytic hydrogenation and biocatalysis.

WuXi XDC’s mission, “Linking innovation to health,” reflects their dedication to providing an open-access platform with comprehensive capabilities and technologies in the global ADC and bioconjugate industry. With a workforce of over 1,000 skilled employees, the company is poised to sustain its leadership in the fast-growing bioconjugation CRDMO market, continually empowering partners to advance healthcare innovations worldwide